As you may have already known, Rapid Novor is a world leader in the antibody/protein sequencing business. But, what you should also know is that we pride ourselves on the unique R&D capability of advancing new technologies and scientific breakthroughs in the field of protein sequencing with mass spectrometry. We believe that the game-changing technologies we are diligently working on will soon rock the world! With the new addition of Dr. Liqiang Yang to Rapid Novor, we are one big step closer to our brighter future.
Liqiang received his Ph.D. degree in Statistics from the North Carolina State University, Raleigh, NC, USA in 2000, and a B.S degree in Mathematics from the Peking University, Beijing, China in 1995.
Liqiang’s rich industrial experiences in drug development started from his graduate school days when he spent over a year as intern biostatistician at one of the largest CROs in the world – PPD. Before joining Rapid Novor, Liqiang had been working in the oncology drug development for over 16 years, of which, 3 years at a CRO company as Senior Biostatistician, 4 years at Amgen Oncology as Manager/Senior Manager of Biostatistics, 8 years at Pfizer Oncology as Associate Director/Director in Clinical Biostatistics, and 1 year at Tocagen as Executive Director and Head Of Biometrics. Liqiang is an expert in developing new drugs, especially cancer drugs. From proof of concept to regulatory approval; from clinical trial design to R&D strategy.
Strong belief in the broader applications of protein sequencing in the medical field is the reason that Liqiang can’t wait to join Rapid Novor. Located in one of the biotechnology centers of the world – San Diego, California, Liqiang will play a critical role in linking our advanced technology with the booming biotechnology industry.
Besides his work, Liqiang is a die-hard soccer fan. And, he loves all kinds of good foods, craft beers, music, movies, poetry and poultry… Having a free-range chicken farm is one of his career goals too.
Newsletter for All Things Protein Sequencing
Breakthrough Bispecific Antibody R&D Techniques, Apr 20 11:00am EST.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and developed the first recombinant polyclonal antibody diagnostics.
Talk to Our Scientists.
We Have Sequenced 5000+ Antibodies and We Are Eager to Help You.
Through next generation protein sequencing, Rapid Novor enables timely and reliable discovery and development of novel reagents, diagnostics, and therapeutics. Thanks to our Next Generation Protein Sequencing and antibody discovery services, researchers have furthered thousands of projects, patented antibody therapeutics, and ran the first recombinant polyclonal antibody diagnostics